Skip to main navigation

Skip to Content

Skip to Content

Investors & Media Contact Us LinkedIn Twitter

About Us
Our Focus
- Schizophrenia
- Psychosis in Alzheimer’s Disease
Pipeline & Programs
Patient Resources
Culture & Careers

Event Details

Overview
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
Investor Resources
Media Kit

Karuna Therapeutics – Phase 3 EMERGENT-3 trial Topline Data Results

Mar 20, 2023 at 8:00 AM EDT

Click here for webcast

Supporting Materials

Topline results: Phase 3 EMERGENT-3 trial of KarXT in schizophrenia 2.3 MB

Print Page Email Page RSS Feeds Email Alerts

About Us
Our Focus
Pipeline & Programs
Patient Resources
Culture & Careers
Investors & Media
Contact Us

Connect with us on LinkedIn Twitter

Copyright 2022 Karuna Therapeutics™. All Rights Reserved. Privacy Policy. Terms of Use. Top

Top